Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743662 · ClinicalTrials.gov registry record · Phase 2
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT03743662: Active Phase 2 study of Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03743662 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03743662, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
Primary Outcome
in participants with recurrent glioblastoma (first recurrence)treated with re-irradiation with concurrent nivolumab (as well as bevacizumab if the investigator feels that the patient benefits from the addition) followed by adjuvant nivolumab in two parallel cohorts.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- PROCEDURE Re-resection
- RADIATION Re-irradiation (RT)
Study Locations (11)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Connecticut
- Hartford Healthcare (Data Collection) - Hartford
Indiana
- Indiana University (Data Collection Only) - Indianapolis
Pennsylvania
- Lehigh Valley Health Network (Data Collection Only) - Allentown
Vermont
- University of Vermont Medical Center (Data Collection Only) - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What the registry record for NCT03743662 still lists
NCT03743662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03743662 lists 11 locations in 6 states (New York, New Jersey, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03743662 about?
NCT03743662 is a clinical study titled "Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma". This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
What is the current status of trial NCT03743662?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-11-12. Estimated completion is 2026-11.
What conditions does trial NCT03743662 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03743662?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), Re-resection (PROCEDURE), Re-irradiation (RT) (RADIATION).
Who is sponsoring clinical trial NCT03743662?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03743662 being conducted?
This trial has 11 study locations across Connecticut, Indiana, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03743662's enrollment target sits among peer trials
39 107th of 199 higher than 91 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI